Shionogi’s Pirespa Obtains MHLW Approval
This article was originally published in PharmAsia News
Executive Summary
Japan's Ministry of Health, Labor and Welfare approved Oct. 16 Shionogi's Pirespa (pirfenidone), indicated to treat idiopathic pulmonary fibrosis. Considering 51.7 percent of clinical studies patients developed solar photosensitivity, MHLW also cautions about exposure to sunlight while taking the drug. The ministry has notified physician associations about the drug's proper use. Physicians should inform patients of the possibilities of skin cancer caused by exposure to sunlight, and patients should avoid sun burn and direct exposure to ultraviolet light. (Click here for more - Japanese language